ALTSHULER DAVID

EVP Altshuler sold 3,231 shares of VRTX at $510.00 (down 0.6% from 52-week high); holds 23,281 post-sale.

On 2025-03-13, DAVID ALTSHULER, EVP and Chief Scientific Officer, sold 3,231 shares at $510.00, a price very near the stock's 52-week high of $516.74. His holdings fell from 26,512 to 23,281 shares, a -12.2% reduction. At the same-ticker level, Altshuler has executed three prior measurable sales at VERTEX, all of which posted positive 90-day returns (+7.3%, +4.8%, +6.0%), meaning none were well-timed by the sell-timing definition (he sold before subsequent stock appreciation). His cross-ticker track record across six prior sells shows an average 90-day return of +4.7% and a 0.00% well-timed rate, indicating a pattern of selling ahead of gains rather than ahead of declines. This sale occurs in a context where VRTX is fundamentally profitable on a quarterly basis ($1.0B net income on $2.8B revenue last quarter) and has delivered +11.9% returns over the prior 30 days, though note that full-year net income was negative, creating a mixed profitability picture.

EVP/CSO Altshuler sold 3,231 shares of VRTX at $500.00 (3/10/25); stock -4.1% from 52-week high.

David Altshuler, the company's Chief Scientific Officer, sold 3,231 shares at $500.00 on 2025-03-10, reducing his VRTX holdings by 10.9% from 29,743 to 26,512 shares. The sale occurred near the 52-week high ($516.74), with the stock currently trading -4.1% from that peak. His prior VRTX sales (5 trades over the past year) posted an average 90-day return of +4.1%, with 0 of 4 prior measurable sales being well-timed—the stock had risen after those sales, suggesting his past exits underperformed. This transaction's significance is moderated by the company's strong fundamentals: annual revenue growth of +11.7% and a $1.0B quarterly net income, though full-year profitability remains negative. The timing of this sale near the 52-week high and post-transaction price momentum (+5.4% in the 30 days following) warrant investor attention to any forward commentary from management on product or pipeline developments.

EVP David Altshuler sold 3,231 VRTX shares at $490.00 ($1.6M); retains 29,743 shares post-sale.

David Altshuler, Chief Scientific Officer, sold 3,231 shares (9.8% of pre-transaction holdings) for $1,583,190.00, reducing his stake from 33.0K to 29.7K shares. His prior four sales at VRTX each yielded positive 90-day returns (+7.3%, +4.8%, +6.0%, +0.6%), meaning the stock rose after those sales; his cross-ticker track record shows 4 prior sells with an average 90-day return of +4.7%, indicating his historical sales have not preceded declines. The current $491.64 price is -4.9% from the 52-week high and +6.9% from 90 days ago, while Vertex reported +11.7% annual revenue growth and positive quarterly net income of $1.0B, despite a full-year loss. This disposal does not align with a pattern of well-timed exits; rather, it extends a history in which Altshuler's sales have coincided with subsequent stock appreciation.